



Copy to and Mail

**BOX AF**

COPY OF PAGES  
ORIGINALLY FILED

Attorney's Docket No. 5784-25 (35784/172864)

RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED  
PROCEDURE - EXAMINING GROUP 1653

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Shirley *et al.* Confirmation No.: Not yet assigned  
Appl. No.: 09/188,051 Group Art Unit: 1653  
Filed: November 6, 1998 Examiner: Kam, C.  
For: COMPOSITIONS PROVIDING FOR INCREASED IGF-I SOLUBILITY

September 3, 2002

BOX AF  
Commissioner for Patents  
Washington, DC 20231

**RECEIVED**

SEP 12 2002

TECH CENTER 1600/2900

**AMENDMENT AFTER FINAL ACTION  
PURSUANT TO 37 C.F.R. § 1.116**

Sir:

This Amendment is responsive to the Final Office Action of May 31, 2002.

Please amend the above-identified application as follows:

In the Claims:

Please amend the claims to read as follows:

31. (Twice amended) The composition of claim 29, wherein said solubilizing compound is selected from the group consisting of arginine, N-acetyl-arginine, a dipeptide containing arginine, and a tripeptide containing arginine, wherein said dipeptide or said tripeptide increases solubility of said IGF-I or analogue thereof at a pH of at least about pH 5.5

35. (Amended) The composition of claim 34, wherein said arginine is present in a molar concentration range of about 10 mM to about 1 M.

36. (Amended) The composition of claim 35, wherein said arginine is present in a molar concentration range of about 15 mM to about 500 mM.